Anika Therapeutics price target raised to $17 from $16 at Barrington

Barrington analyst Michael Petusky raised the firm’s price target on Anika Therapeutics (ANIK) to $17 from $16 and keeps an Outperform rating on the shares. The company reported a Q4 beat, the analyst tells investors in a research note. The firm says that despite yesterday’s 16% rally, Anika remains “meaningfully undervalued.”